Transmembrane Amino Acid Transporters in Shaping the Metabolic Profile of Breast Cancer Cell Lines: The Focus on Molecular Biological Subtype DOI Creative Commons

Elena I. Dyachenko,

Lyudmila V. Bel’skaya

Current Issues in Molecular Biology, Journal Year: 2024, Volume and Issue: 47(1), P. 4 - 4

Published: Dec. 25, 2024

Amino acid metabolism in breast cancer cells is unique for each molecular biological subtype of cancer. In this review, the features cell are considered terms changes amino composition due to activity transmembrane transporters. addition main signaling pathway PI3K/Akt/mTOR, oncogene c-Myc, HIF, p53, GATA2, NF-kB and MAT2A have a direct effect on cells, their growth proliferation, as well maintenance homeostatic equilibrium. A distinctive feature luminal subtypes from TNBC ability perform gluconeogenesis. Breast cancers with positive expression HER2 receptor, contrast subtype, active synthesis consumption fatty acids. It interesting note that transporters exhibit depending pH level inside cell. most aggressive forms or gradual progression disease, will also change, which directly affect Using lines presented we can trace characteristic inherent develop optimal therapeutic targets.

Language: Английский

Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis DOI Open Access

Mengchao YANG,

Yufeng Mu,

Xiaoyun Yu

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 176, P. 116783 - 116783

Published: May 25, 2024

During tumor development, the itself must continuously generate new blood vessels to meet their growth needs while also allowing for invasion and metastasis. One of most common features tumors is hypoxia, which drives process angiogenesis by regulating microenvironment, thus adversely affecting prognosis patients. In addition, overcome unsuitable environments growth, such as nutrient deficiency, hyperacidity, immunosuppression, microenvironment (TME) coordinates in several ways restore supply oxygen nutrients remove metabolic wastes. A growing body research suggests that hypoxia interact through a complex interplay crosstalk, inextricably linked TME. Here, we review TME's positive contribution from an angiogenesis-centric perspective considering objective impact hypoxic phenotypes status limitations current angiogenic therapies.

Language: Английский

Citations

11
Thymoquinone and Metabolic Reprogramming in Breast Cancer: A New Dimension From Proteomic Analysis DOI Open Access
Tuğcan Korak, Merve Gülşen Bal Albayrak, Murat Kasap

et al.

Journal of Biochemical and Molecular Toxicology, Journal Year: 2025, Volume and Issue: 39(1)

Published: Jan. 1, 2025

ABSTRACT Thymoquinone (TQ) has shown antitumorigenic effects in breast cancer; however, its detailed impact on cell signaling mechanisms requires further investigation. This study aims to elucidate the molecular behind TQ's antiproliferative cancer by analyzing proteome‐level changes. MCF‐7 cells were treated with 15 µM TQ, inhibitory concentration (IC50), for 48 h. Proteins from and untreated (control) groups isolated subjected liquid chromatography–tandem mass spectrometry (LC–MS/MS) proteomic analysis. Identified proteins functionally annotated, hub identified using Cytoscape software, verification conducted through Western blot Label‐free quantitation 629 master proteins, 104 upregulated 477 downregulated TQ‐treated samples compared controls. Among these, 150 showed dramatic regulation, including 11 139 ribosomal emerging as central. The heatmap demonstrated robust clustering of replicates. Functional annotations indicated that TQ significantly impacts crucial such carbon metabolism, amino acid biosynthesis, protein synthesis, citrate cycle, essential metabolic reprogramming. identifies novel targets associated reprogramming, previously underexplored effects, highlighting their pivotal role anticancer cancer. These findings could lay groundwork developing future TQ‐based therapies.

Language: Английский

Citations

1
Chitosan and hyaluronic acid in breast cancer treatment: Anticancer efficacy and nanoparticle and hydrogel development DOI
Yanlin Jiang, Yu Cao, Yiqun Yao

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 301, P. 140144 - 140144

Published: Jan. 21, 2025

Language: Английский

Citations

1
CDK4/6 as a Therapeutic Target in HR+/HER2− Breast Cancer Cells—Current Treatment Status DOI Open Access

Katherine Krupa,

Anna Liszcz-Tymoszuk,

Natalia Czerw

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 1039 - 1039

Published: March 20, 2025

Breast cancer is the most frequently diagnosed neoplasm in world. It can be classified into four main subtypes, each of them showing differences expression hormone receptor (HR), human epidermal growth factor 2 (HER2), and cell metabolism. Since 2015, when The U.S. Food Drug Administration (FDA) approved first cyclin-dependent kinase 4 6 (CDK4/6) inhibitor that regulates cycle, treatment HR+/HER2− BC has become much more effective. Currently, palbociclib, ribociclib, abemaciclib are often used both combination with endocrine therapy as well monotherapy. Their application been extensively verified many clinical trials such PALOMA-1,2,3, MONALEESA-1,2,3,7, MONARCH-1,2,3, which allowed verification their effectiveness, dosage, adverse effects. Subsequent studies, MonarchE NATALEE, examined role these inhibitors adjuvant therapy, at verifying safety. Moreover, dalpiciclib being investigated treatment. This article will summarize efficacy, recommendations, toxicity profile between also discuss possibility using breast cancer.

Language: Английский

Citations

1
Novel sulfonamide-indolinone hybrids targeting mitochondrial respiration of breast cancer cells DOI

Sama W.A. Helmy,

Amal Kamal Abdel‐Aziz, Eman M.E. Dokla

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 268, P. 116255 - 116255

Published: Feb. 17, 2024

Language: Английский

Citations

7
Breast Cancer Chemoresistance: Insights into the Regulatory Role of lncRNA DOI Open Access

Seyedeh Tayebeh Ahmadpour,

Charlotte Orré,

Priscila Bertevello

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(21), P. 15897 - 15897

Published: Nov. 2, 2023

Long noncoding RNAs (lncRNAs) are a subclass of composed more than 200 nucleotides without the ability to encode functional proteins. Given their involvement in critical cellular processes such as gene expression regulation, transcription, and translation, lncRNAs play significant role organism homeostasis. Breast cancer (BC) is second most common worldwide evidence has shown relationship between aberrant lncRNA BC development. One main obstacles control multidrug chemoresistance, which associated with deregulation multiple mechanisms efflux transporter activity, mitochondrial metabolism reprogramming, epigenetic regulation well apoptosis autophagy. Studies have large number pathways. However, underlying mechanism not clearly elucidated. In this review, we present principal chemoresistance that can be directly or indirectly regulated by lncRNA, highlighting importance controlling chemoresistance. Understanding these deep detail may interest clinical outcome patients could used therapeutic targets overcome therapy resistance.

Language: Английский

Citations

14
Osteopontin, a Key Multifaceted Regulator in Tumor Progression and Immunomodulation DOI Open Access
Venketesh K. Panda,

Barnalee Mishra,

Angitha N Nath

et al.

Published: May 13, 2024

Tumor microenvironment (TME) is composed of various cellular components such as tumor cells, stromal cells including fibroblasts, adipocytes, mast cell, lymphatic vascular and infiltrating immune macrophages, dendritic lymphocytes. The intricate interplay between these influences growth, metastasis therapy failure. Significant advancements in breast cancer have resulted a substantial decrease mortality. However, existing treatments frequently result toxicity nonspecific side effects. Therefore, improving targeted drug delivery increasing the efficacy drugs are crucial for enhancing treatment outcome reducing burden toxicity. In this review, we provided an overview how stroma-derived osteopontin (OPN) plays key role regulating oncogenic potential cancers breast. Next, dissected signalling network by which OPN regulates progression through interaction with selective integrins CD44 receptors. This review addresses latest advancement splice variants OPN-mediated tumor-stromal interaction, EMT, CSCs enhancement, immunomodulation, metastasis, chemoresistance, metabolic reprogramming further suggest that might be therapeutic target prognostic biomarker evolving landscape management.

Language: Английский

Citations

6
Osteopontin: A Key Multifaceted Regulator in Tumor Progression and Immunomodulation DOI Creative Commons
Venketesh K. Panda,

Barnalee Mishra,

Angitha N. Nath

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(7), P. 1527 - 1527

Published: July 9, 2024

The tumor microenvironment (TME) is composed of various cellular components such as cells, stromal cells including fibroblasts, adipocytes, mast lymphatic vascular and infiltrating immune macrophages, dendritic lymphocytes. intricate interplay between these influences growth, metastasis therapy failure. Significant advancements in breast cancer have resulted a substantial decrease mortality. However, existing treatments frequently result toxicity nonspecific side effects. Therefore, improving targeted drug delivery increasing the efficacy drugs crucial for enhancing treatment outcome reducing burden toxicity. In this review, we provided an overview how stroma-derived osteopontin (OPN) plays key role regulating oncogenic potential cancers breast. Next, dissected signaling network by which OPN regulates progression through interaction with selective integrins CD44 receptors. This review addresses latest roles splice variants OPN-mediated tumor-stromal interaction, EMT, CSC enhancement, immunomodulation, metastasis, chemoresistance metabolic reprogramming, further suggests that might be therapeutic target prognostic biomarker evolving landscape management.

Language: Английский

Citations

5
Research progresses and hotspots on glucose metabolic reprogramming in breast cancer: a bibliometric analysis over the past two decades DOI Creative Commons
Lei Huang,

Wenyue Zhao,

Lamei Sun

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 14

Published: Jan. 14, 2025

Background Abnormal energy metabolism is a prominent characteristic of cancers. Increasing evidence has suggested the involvement glucose reprogramming in progression breast cancer (BC). This article aims to provide comprehensive overview BC through bibliometric analysis. Methods Relevant literatures published from 2004 2024 were searched Web Science Core Collection database, and analysis was conducted using VOSviewer, CiteSpace, Bibliometrix. Results In total, 957 publications reporting included, showing an increasing trend annual publication outputs. China ranked first outputs, United States America (USA) had dominant place citation counts. The research achievements Thomas Jefferson University USA at forefront widely cited. Lisanti, Michael P., Sotgia, Federica most productive authors. Keyword that mechanisms related therapeutic strategies hotspots. Conclusion study, for time, elucidated progresses hotspots on BC, highlighting its potential role treating BC. Considering glycolytic complex biological process, it imperative countries enhance cooperation pursuit effective antimetabolic therapies overcome challenges treatment.

Language: Английский

Citations

0
The role of circular RNAs in glucose metabolic reprogramming: impact on cancer progression and therapeutic implications in breast cancer DOI Open Access
Yiran Liang, Qifeng Yang

Journal of Cancer Metastasis and Treatment, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

Breast cancer is one of the most common female malignant tumors, which seriously endangers human health. Glucose metabolic reprogramming in rapidly proliferating cancers drives increased glycolysis to meet energy needs, promoting tumor growth, acidifying microenvironment, and impairing immune function, diminishes therapeutic efficacy. Circular RNAs (circRNAs), as key regulators cellular processes, are increasingly recognized for their involvement cancer. Concurrently, specific circRNAs could be released by cells via exosomes facilitate intercellular communication, significantly impacting glucose metabolism, progression, therapy resistance. However, role breast mechanisms regulating metabolism remain unclear. Therefore, elucidating these regulatory pathways provide valuable insights developing targeted strategies exploit vulnerabilities improve prognosis

Language: Английский

Citations

0